scholarly journals Successful Treatment of Antiepileptic Drug-Induced DRESS Syndrome with Pulse Methylprednisolone

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Celebi Kocaoglu ◽  
Ceyda Cilasun ◽  
Ece Selma Solak ◽  
Gulcan S. Kurtipek ◽  
Sukru Arslan
Keyword(s):  
Valproic Acid ◽  
Present Report ◽  
Treatment Modalities ◽  
Dress Syndrome ◽  
Internal Organs ◽  
Drug Induced ◽  
Pulse Methylprednisolone ◽  
Lymph Node Enlargement ◽  
Life Threatening ◽  
Systemic Symptoms

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but potentially life-threatening syndrome characterized by skin rash, fever, lymph node enlargement, and involvement of internal organs. It is most commonly induced by aromatic anticonvulsants and antibiotics. Nonaromatic anticonvulsants are rarely encountered as the causes of DRESS syndrome. In the present report, three discrete cases with DRESS syndrome developing due to three antiepileptic drugs, including valproic acid (nonaromatic), carbamazepine (aromatic), and lamotrigine (aromatic), and their treatment modalities were aimed to be discussed in light of the literature. To the best of our knowledge, our cases are the first children to be treated with pulse methylprednisolone in the literature.

scholarly journals Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
James C. Di Palma-Grisi ◽  
Kesav Vijayagopal ◽  
Muhammad A. Muslimani
Keyword(s):  
Monoclonal Antibodies ◽  
Case Reports ◽  
Maculopapular Rash ◽  
Phase Iii ◽  
Dress Syndrome ◽  
Drug Induced ◽  
Diagnostic Reliability ◽  
Phase Iii Clinical Trials ◽  
Life Threatening ◽  
Systemic Symptoms

Background. Monoclonal antibodies constitute a potent and broadly tolerable drug class, representing for some conditions the first newly approved treatment in years. As such, many are afforded “fast-track” or “breakthrough therapy” designations by the U.S. Food and Drug Administration, leading to provisional approval before Phase III clinical trials are reported. Although these drugs are usually safe, some patients experience life-threatening complications—myositis and encephalitis have led to permanent or temporary recalls. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a hypersensitivity condition easily missed due to its long incubation period and nonspecific presentation. This minireview is primarily intended as an abbreviated guide for practitioners who may be using these powerful treatments. Methodology. We searched PubMed using a string of symptoms consistent with DRESS syndrome and monoclonal antibodies approved by the FDA since 2015. Then, we excluded studies reporting dermatological complications of reactivation of nonherpetic infection, immunodeficiency-related infection, or reactions to the injection site or infusion. We searched for and accessed prior reviews and background studies via PubMed, Mendeley, and Google Scholar. Results. Two cases of DRESS syndrome were identified in the literature, both the result of treatment with daclizumab. There was one additional case of encephalitis without cutaneous symptoms caused by daclizumab. Drug-induced hypersensitivity dermatitis was reported following treatment with nivolumab and two cases of combination treatment with ipilimumab and either nivolumab or durvalumab produced maculopapular rash and bullae in the first patient and lichenoid dermatitis and blisters in the second patient. Conclusions. Daclizumab was the only recently approved monoclonal antibody associated with DRESS syndrome as such. Limitations in the diagnostic reliability of DRESS syndrome as a clinical entity and the lack of negative clinical trial reporting suggest enhanced vigilance on the part of clinicians and regulators may be warranted.

scholarly journals Drug rash with eosinophilia and systemic symptoms, uncommon and commonly missed

2019 ◽  
Vol 6 (4) ◽  
pp. 1360
Author(s):  
Dona Das ◽  
Dinesh E. Ragav ◽  
A. Nasreen Begum
Keyword(s):  
Hypersensitivity Reaction ◽  
Blood Count ◽  
Dress Syndrome ◽  
Rare Form ◽  
Drug Induced ◽  
Life Threatening ◽  
Rapid Pace ◽  
Drug Rash ◽  
Systemic Symptoms ◽  
Kidney Liver

Drug Rash with eosinophilia and systemic symptoms, also called DRESS syndrome, is a rare form of drug induced hypersensitivity reaction that presents with skin eruptions, blood count abnormalities (eosinophilia) and internal organ involvement (lung, kidney, liver), making it life threatening at a rapid pace. The most commonly affected organ is liver, mimicking condition similar to acute hepatitis.

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Induced by Imatinib

2019 ◽  
Vol 14 (2) ◽  
pp. 151-154 ◽  
Author(s):  
F. Zgolli ◽  
I. Aouinti ◽  
O. Charfi ◽  
T. Badri ◽  
S. Elaidli ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Liver Function Tests ◽  
Exceptional Case ◽  
Favourable Outcome ◽  
Dress Syndrome ◽  
Drug Induced ◽  
Life Threatening ◽  
Drug Rash ◽  
Systemic Symptoms ◽  
European Registry

Introduction: Imatinib is the treatment of choice in patients with locally advanced or metastatic gastrointestinal stromal tumours (GIST). Clinical tolerance of imatinib is excellent except for the common adverse drug reaction (ADR). Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-threatening drug-induced hypersensitivity reaction, characterized by cutaneous eruptions, fever, diffuse lymphadenopathy, along with eosinophilia, and elevated liver function tests. This ADR is rarely reported with imatinib. Only four cases of DRESS syndrome associated with imatinib have already been published. Case Report:We report an exceptional case of DRESS syndrome associated with imatinib in a 46 year-old woman with GIST. Two weeks after she had started imatinib therapy, she developed a skin rash, with eosinophilia and elevated liver tests. Plasma level of imatinib was within the therapeutic range. Imatinib was immediately discontinued. A favourable outcome was slowly observed after the drug had been stopped. Results and Conclusion: This case was scored three according to the European Registry of Severe Cutaneous Adverse Reactions Study Group (RegiSCAR). The Naranjo score for imatinib was five (probable).

scholarly journals DRESS syndrome due to clobazam: a case report

2020 ◽  
Vol 9 (12) ◽  
pp. 1906
Author(s):  
M. Faraz Qureshi ◽  
A. N. Dattatari
Keyword(s):  
Case Report ◽  
Hypersensitivity Reaction ◽  
Seizure Disorder ◽  
Dress Syndrome ◽  
Internal Organs ◽  
Idiosyncratic Reaction ◽  
Life Threatening ◽  
History Of ◽  
Drug Rash ◽  
Systemic Symptoms

Drug rash (or reaction) with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening hypersensitivity reaction to drugs characterized by rash, fever, lymphadenopathy, hematologic abnormalities, and involvement of internal organs. Initially coined in 1996, the term is used to refer to an idiosyncratic reaction to several drugs, the most common of which are carbamazepine, allopurinol, sulfasalazine, and phenobarbital. We report the case of DRESS related to clobazam in a 38-year-old female with a history of a complex seizure disorder.

scholarly journals Dress Syndrome - A Case Report

2016 ◽  
Vol 8 (2) ◽  
pp. 95-100 ◽  
Author(s):  
Zorana Kremić ◽  
Željko P. Mijušković ◽  
Lidija Kandolf-Sekulović
Keyword(s):  
Supportive Therapy ◽  
Dress Syndrome ◽  
Drug Induced ◽  
Systemic Manifestations ◽  
Inflammatory Drugs ◽  
Hematological Abnormalities ◽  
Systemic Symptoms ◽  
Generalized Epilepsy ◽  
Maculopapular Exanthema ◽  
Induced Reaction

Abstract The drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an adverse drug-induced reaction that occurs most commonly after exposure to drugs, most frequently anticonvulsants, sulfa derivates, antidepressants, nonsteroidal anti-inflammatory drugs, and antimicrobials. We present a 61-year-old male, with a generalized maculopapular exanthema on the trunk, face, extremities, palms, soles, palate, and fever (38°C). His medical history was notable for generalized epilepsy, treated with carbamazepine during 1 month. The diagnosis of DRESS syndrome was confirmed by specific RegiSCAR criteria. In our case, skin eruptions were successfully treated with oral methylprednisolone, cephalexin, and topical corticosteroid ointment. In conclusion, although the mechanisms of this syndrome are not completely understood, numerous cases were reported in children and adults. This syndrome should be considered in every patient with skin eruption, fever, eosinophilia, liver and hematological abnormalities. Prompt recognition, supportive therapy and initiation of corticosteroids may prevent systemic manifestations.

scholarly journals LAMOTRIGINE INDUCED DRESS SYNDROME

2017 ◽  
Vol 10 (9) ◽  
pp. 3
Author(s):  
Saurab Agarwal ◽  
Balaji Ommurugan ◽  
Amita Priya ◽  
Mohan Amberkar ◽  
Meena Kumari Kamalkishore
Keyword(s):  
Early Detection ◽  
Early Diagnosis ◽  
Hypersensitivity Reaction ◽  
Rare Case ◽  
Dress Syndrome ◽  
Early Recovery ◽  
Life Threatening ◽  
Drug Rash ◽  
Systemic Symptoms ◽  
Life Threatening Event

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, is a type of hypersensitivity reaction, mainly due to anti-epileptic drugs. Lamotrigine is a newer broad spectrum antiepileptic that can be used in both children and adults. Lamotrigine induced DRESS syndrome is a rare case with incidence of 1/1000 to 1/10000. This syndrome manifests as rash, fever, tender lymphadenopathies, hepatitis, and eosinophilia. This case highlights the need for early diagnosis and treatment of such a rare and life threatening event because early detection of the condition leads to early recovery of the patient. Further re-exposure to the drug should be avoided.  

Movement Disorders Emergencies

2019 ◽  
Vol 39 (01) ◽  
pp. 125-136 ◽  
Author(s):  
Suraj Rajan ◽  
Bonnie Kaas ◽  
Emile Moukheiber
Keyword(s):  
Movement Disorders ◽  
Serotonin Syndrome ◽  
Clinical Presentation ◽  
Treatment Modalities ◽  
Drug Induced ◽  
Status Dystonicus ◽  
Life Threatening ◽  
At Risk Populations ◽  
Clinical Phenomenology ◽  
Malignant Catatonia

AbstractMany acute and potentially life-threatening medical conditions have hyperkinetic or hypokinetic movement disorders as their hallmark. Here we review the clinical phenomenology, and diagnostic principles of neuroleptic malignant syndrome, malignant catatonia, serotonin syndrome, Parkinsonism hyperpyrexia, acute parkinsonism, acute chorea-ballism, drug-induced dystonia, and status dystonicus. In the absence of definitive lab tests and imaging, only a high index of clinical suspicion, awareness of at-risk populations, and variations in clinical presentation can help with diagnosis. We also discuss the principles of management and rationale behind treatment modalities in the light of more recent evidence.

scholarly journals Phenytoin induced life threatening macroglossia in a child

2013 ◽  
Vol 04 (01) ◽  
pp. 75-77 ◽  
Author(s):  
Rakesh Mondal ◽  
Sumantra Sarkar ◽  
Tapas Sabui ◽  
Partha Pratim Pan
Keyword(s):  
Drug Reaction ◽  
Hereditary Angioedema ◽  
Dress Syndrome ◽  
Medical College ◽  
Life Threatening ◽  
Systemic Symptoms

ABSTRACTIsolated acquired macroglossia of tongue rarely reported. It occurs due to causes like hereditary angioedema, localized angioedema, etc., Here we describe an 8‑year‑old boy developing life threatening localized angioedema of tongue due to phenytoin without any association with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome or pseudolymphoma encountered in rural medical college. Anticonvulsants, that is, phenytoin induced this isolated peculiar complication, which was not described before.

scholarly journals Drug Reaction with Eosinophilia and Systemic Symptoms: A Complex Interplay between Drug, T Cells, and Herpesviridae

2021 ◽  
Vol 22 (3) ◽  
pp. 1127
Author(s):  
Luckshman Ganeshanandan ◽  
Michaela Lucas
Keyword(s):  
Drug Reaction ◽  
Human Leukocyte ◽  
Molecular Techniques ◽  
Dress Syndrome ◽  
Complex Interplay ◽  
Drug Induced ◽  
Leukocyte Antigen ◽  
Systemic Symptoms ◽  
Delayed Hypersensitivity Reaction

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, also known as drug induced hypersensitivity (DiHS) syndrome is a severe delayed hypersensitivity reaction with potentially fatal consequences. Whilst recognised as T cell-mediated, our understanding of the immunopathogenesis of this syndrome remains incomplete. Here, we discuss models of DRESS, including the role of human leukocyte antigen (HLA) and how observations derived from new molecular techniques adopted in key studies have informed our mechanism-based understanding of the central role of Herpesviridae reactivation and heterologous immunity in these disorders.

Sign in / Sign up

Export Citation Format

Share Document